Thrombin-Activated Receptors: Promising Targets for Cancer Therapy?

Author(s): M. T. Garcia-Lopez, M. Gutierrez-Rodriguez, R. Herranz

Journal Name: Current Medicinal Chemistry

Volume 17 , Issue 2 , 2010

Become EABM
Become Reviewer


In addition to the key role of thrombin in blood coagulation, this multifunctional serine protease activates platelets and regulates the behavior of other cells through G-protein coupled protease activated receptors (PARs). PAR-1 is the principal thrombin-activated receptor involved in platelet aggregation and in endothelial and tumor cell proliferation. PAR-1 is overexpressed in invasive and metastatic tumors and the expression levels directly correlate with the degree of invasiveness of the cancer. In an attempt to give some insight into the perspectives of targeting PAR-1 in cancer and angiogenesis, this review provides an overview on the thrombin/PAR-1 interaction, receptor activation, signaling, desensitization and dysregulation mechanisms in relation to these diseases. A central aspect of this review is that directed to summarize the approaches that have been followed to the search of PAR-1 antagonists, illustrating with some significant examples. Attention is called to the scarce data concerning the effects of these antagonists on anticancer assay models.

Keywords: Cancer, Angiogenesis, Protease-Activated Receptors, Thrombin-Activated Receptors, PAR-1, PAR-1 Agonists and Antagonists

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [109 - 128]
Pages: 20
DOI: 10.2174/092986710790112639
Price: $65

Article Metrics

PDF: 19